Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Calu-3 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) Autophagy (2) Cathepsin (2) CDK (1) Chloride Channel (1) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (1) Influenza Virus (1) Parasite (2) Potassium Channel (2) PROTACs (1) ROS Kinase (2) SARS-CoV (21) Ser/Thr Protease (3) Virus Protease (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Infection (24) Inflammation/Immunology (2) Metabolic Disease (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor Programmed Cell Death 4 (PDCD4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155016

SARS-CoV-2-IN-46	SARS-CoV	Infection
SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC₅₀ of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research .

HY-155014

SARS-CoV-2-IN-44	SARS-CoV	Infection
SARS-CoV-2-IN-44, a inhibitor of SARS-CoV-2, inhibits viral replication, with an EC₅₀ of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .

HY-176280

SARS-CoV-2-IN-115	SARS-CoV Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
SARS-CoV-2-IN-115 (Compound 3e) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-115 has potent antiviral activity against SARS-CoV-2 in infected Calu-3 cells (EC₅₀: 1.7  μM). SARS-CoV-2-IN-115 effectively inhibits the activity of human dihydroorotate dehydrogenase (HsDHODH) (IC₅₀: 1.5  μM). SARS-CoV-2-IN-115 preserves immune response without antiproliferative effects on CD4 T cells .

HY-155015

SARS-CoV-2-IN-45	SARS-CoV	Infection
SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC₅₀ of 0.5 μM, and has no evident cytotoxic effect .

HY-163206

SARS-CoV-2-IN-77	Cathepsin SARS-CoV	Infection
SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with K_i values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC₅₀ value of 38.4 nM in Calu-3 cells without showing cytotoxicity .

HY-156325

SARS-CoV-2-IN-62	SARS-CoV	Infection
SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 2.97 μM and 3.82 μM, respectively .

HY-156337

SARS-CoV-2-IN-63	SARS-CoV	Infection
SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 1.99 μM and 1.92 μM, respectively .

HY-173459

N-0920	SARS-CoV	Infection
N-0920 is a potent TMPRSS2 inhibitor with an IC₅₀ of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC₅₀s values of 300 pM and 90 pM, respectively .

HY-156441

SARS-CoV-2-IN-65	SARS-CoV	Infection
SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .

HY-168917

9-AMN	SARS-CoV Virus Protease	Infection
9-AMN is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC₅₀ of 4.55 µM and 4.15 µM. 9-AMN inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC₅₀ of 1.04 µM and 2.35 µM .

HY-162719

RH12	SARS-CoV	Infection
RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC₅₀ is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC₅₀ is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC₅₀ of 17.5 nM .

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-157805

PROTAC SARS-CoV-2 Mpro degrader-2	PROTACs SARS-CoV	Infection
PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 M ^pro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC₅₀ = 10.8 μM), HCoV-OC43 (EC₅₀ = 1.6 μM) and HCoV-229E (EC₅₀ = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC₅₀ of 0.89 μM .

HY-162492

Influenza A virus-IN-14	Influenza Virus	Infection
Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC₅₀ of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC₅₀ of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .

HY-158405

PAV-104	SARS-CoV	Infection
PAV-104 inhibits SARS-CoV-2 replication, with the MOI of 0.01. PAV-104 can interact with SARS-CoV-2 nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly .

HY-176453

Allobetulone N066-0059	Chloride Channel	Cancer
Allobetulone (N066-0059) is a TMEM16A inhibitor (IC₅₀: 0.24 µM). Allobetulone (N066-0059) can be used in anti-cancer research .

HY-170894

SARS-CoV-2 Mpro-IN-37	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 main protease (M ^pro) inhibitor, with an IC₅₀ of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M ^pro and MERS-CoV M ^pro with IC₅₀s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity .

HY-B1624C

Debrisoquin hydrobromide Debrisoquine hydrobromide; Isocaramidine hydrobromide; Ro 5-3307/1 hydrobromide	SARS-CoV Ser/Thr Protease	Infection
Debrisoquine (Ro 5-3307/1) hydrobromide is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquine hydrobromide can be used for antiviral research .

HY-W195509

Debrisoquin hydroiodide Debrisoquine hydroiodide; Isocaramidine hydroiodide; Ro 5-3307/1 hydroiodide	SARS-CoV Ser/Thr Protease	Infection
Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624). Debrisoquin is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for antiviral research .

HY-B1624

Debrisoquin Debrisoquine; Isocaramidine; Ro 5-3307/1	SARS-CoV Ser/Thr Protease	Infection Cardiovascular Disease
Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin can be used for antiviral research .

HY-B1624A

Debrisoquin hemisulfate Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate	Endogenous Metabolite	Infection Cardiovascular Disease
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin hemisulfate can be used for antiviral research .

HY-15275

BMS-265246 1 Publications Verification	CDK Angiotensin-converting Enzyme (ACE)	Infection Cardiovascular Disease Cancer
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .

HY-17437R

Mefloquine (Standard)	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Standard) is the analytical standard of Mefloquine. This product is intended for research and analytical applications. Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-17437

Mefloquine 3 Publications Verification Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-163029

CTSL/B-IN-1	Cathepsin SARS-CoV	Infection
CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC₅₀s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .

Cat. No.	Product Name	Target	Research Area

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

Debrisoquin hemisulfate Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Endogenous metabolite Isoquinoline Alkaloids Disease Research Fields	Endogenous Metabolite
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin hemisulfate can be used for antiviral research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Calu-3 cells

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products